Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes Sells 1,000 Shares

Share on StockTwits

Cardlytics Inc (NASDAQ:CDLX) CEO Scott D. Grimes sold 1,000 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $30.52, for a total transaction of $30,520.00. Following the sale, the chief executive officer now owns 389,431 shares of the company’s stock, valued at approximately $11,885,434.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Scott D. Grimes also recently made the following trade(s):

  • On Wednesday, January 8th, Scott D. Grimes sold 1,000 shares of Cardlytics stock. The stock was sold at an average price of $66.61, for a total transaction of $66,610.00.

NASDAQ CDLX traded up $1.36 during trading hours on Thursday, hitting $43.00. 34,290 shares of the stock were exchanged, compared to its average volume of 1,414,936. The company has a market cap of $901.92 million, a price-to-earnings ratio of -55.06 and a beta of 1.64. Cardlytics Inc has a 12-month low of $14.14 and a 12-month high of $107.50. The stock has a 50-day moving average of $70.10 and a 200 day moving average of $57.93.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.14. The firm had revenue of $69.29 million during the quarter, compared to analysts’ expectations of $69.19 million. Cardlytics had a negative net margin of 8.15% and a negative return on equity of 19.49%. The firm’s revenue for the quarter was up 44.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.06) earnings per share. On average, analysts expect that Cardlytics Inc will post -0.63 earnings per share for the current year.

Several brokerages have recently weighed in on CDLX. JPMorgan Chase & Co. decreased their target price on shares of Cardlytics from $65.00 to $47.00 and set a “neutral” rating for the company in a research note on Wednesday, March 18th. Bank of America reiterated an “average” rating and set a $100.00 target price on shares of Cardlytics in a research note on Tuesday, January 14th. BidaskClub downgraded shares of Cardlytics from a “buy” rating to a “hold” rating in a research note on Saturday, February 29th. ValuEngine raised shares of Cardlytics from a “sell” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Craig Hallum cut shares of Cardlytics from a “buy” rating to a “hold” rating and cut their price target for the stock from $100.00 to $70.00 in a report on Wednesday, March 4th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $66.57.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new position in shares of Cardlytics in the 1st quarter valued at $336,000. FMR LLC raised its stake in shares of Cardlytics by 2.3% in the 1st quarter. FMR LLC now owns 3,284,572 shares of the company’s stock valued at $54,327,000 after buying an additional 72,847 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of Cardlytics by 25.4% in the 3rd quarter. California Public Employees Retirement System now owns 14,800 shares of the company’s stock valued at $496,000 after buying an additional 3,000 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Cardlytics by 20.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 20,171 shares of the company’s stock worth $675,000 after purchasing an additional 3,468 shares in the last quarter. Finally, State Street Corp increased its position in shares of Cardlytics by 5.0% during the 3rd quarter. State Street Corp now owns 246,945 shares of the company’s stock worth $8,278,000 after purchasing an additional 11,812 shares in the last quarter.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Further Reading: Reverse Stock Split

Insider Buying and Selling by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.